Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Filip JankuHaeseong ParkS Greg CallKiran MadwaniYasuhiro OkiVivek SubbiahDavid S HongAung NaingVivianne M Velez-BravoTamara G BarnesFredrick B HagemeisterGerald S FalchookDaniel D KarpJennifer J WhelerSarina A Piha-PaulIgnacio Garrido-LagunaElizabeth J ShpallLuis E FayadSattva S NeelapuFunda Meric-BernstamRazelle KurzrockMichelle A FanalePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Combined HDAC and mTOR inhibition has salutary activity in patients with relapsed refractory Hodgkin lymphoma and warrants further investigation.